Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CASP1 | P29466 | 2/20 | 0.32 |
| ▸ | CASP7 | P55210 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6604465 | 0.79 | ALDH1A1 (0.33) | KMT2AALDH1A1CASP1CASP7HSD17B10 | |
| SCHEMBL6837806 | 0.78 | KMT2A (0.39) | KMT2AALDH1A1CASP1CASP7HSD17B10 | |
| SCHEMBL6609896 | 0.74 | LMNA (0.50) | KMT2AALDH1A1HSD17B10MEN1KDM4E | |
| SCHEMBL6607683 | 0.69 | ALDH1A1 (0.43) | KMT2AALDH1A1CASP1CASP7HSD17B10 | |
| SCHEMBL6837909 | 0.68 | MAPT (0.47) | KMT2AALDH1A1CASP1CASP7HSD17B10 | |
| SCHEMBL6837900 | 0.66 | KMT2A (0.31) | KMT2AMAPT | |
| SCHEMBL30884171 | 0.66 | AOC3 (0.53) | KMT2AALDH1A1MEN1KDM4EGAA | |
| SCHEMBL4678057 | 0.66 | AOC3 (0.53) | KMT2AALDH1A1MEN1KDM4EGAA | |
| SCHEMBL1287466 | 0.66 | HTR1A (0.37) | GAAMAPTTSHRMAPK1HTT | |
| SCHEMBL10889311 | 0.66 | MEN1 (0.51) | KMT2AALDH1A1MEN1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1110961-B1 | OXYGENIC HETEROCYCLIC COMPOUNDS | KYOWA HAKKO KOGYO KK (JP) | 2004-07-14 | — | — | EP | disclosed |
| US-6376535-B2 | PHOSPHODIESTERASE (PDE) INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-04-23 | — | — | US | disclosed |
| US-20010056117-A1 | Oxygen-containing heterocyclic compounds | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2001-12-27 | — | — | US | disclosed |
| EP-1110961-A1 | OXYGENIC HETEROCYCLIC COMPOUNDS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056117-A1 | Oxygen-containing heterocyclic compounds | CBR1, CBR3, MT-CO1 | KMT2A 1673/4885ALDH1A1 232/4885CASP1 1109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.